Dr. John Goldman CML Chronic Myeloid Leukemia
''Professor John M. Goldman has a long standing interest in the biology and therapy of chronic myeloid leukemia (CML)....
....He is now active as Emeritus Professor of Haematology at Imperial College London and Medical Director of the Anthony Nolan Trust....
... Professor Goldman was the first to autograft patients with CML using peripheral blood stem cells and started allogeneic stem cell transplant for CML in 1980. He pioneered the use of unrelated donors for transplanting CML patients and developed PCR technology for monitoring residual disease. He confirmed the preclinical efficacy of the original tyrosine kinase inhibitor (STI571, now imatinib) in 1997 and first used it in the clinic in 1999. Thereafter he has been involved in development of second generation TKIs, notably dasatinib and nilotinib.""
Extract from the site of iCMLf (International Chronic Myeloid Leukemia Foundation)
VIDEOS
CML Treatment with imatinib
December 2010, iCMLf
Novel agents for treatment of CML with Prof. John Goldman – EHA 2010
August 5, 2010, ecancer.tv
CML Treatment with imatinib
December 2010, iCMLf
Novel agents for treatment of CML with Prof. John Goldman – EHA 2010
August 5, 2010, ecancer.tv
ARTICLES
Remembering John Goldman
December 27, 2013, ICMLf
Professor John M Goldman Past away this afternoon
December 24, 2013, cmlsupport
The 2011 Rowley Prize is awarded to Dr. John Goldman
2011, iCMLf
Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy
August 18, 2011, Haematologica
Initial treatment for patients with CML
January 1, 2009, American Society of Hematology Education Program Book
How I treat chronic myeloid leukemia in the imatinib era
October 15, 2007, Journal Blood
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
October 9, 2003, The New England Journal of Medicine
A History of Leukemia by Dr. John M. Goldman
January 2003, Medscape
The molecular biology of chronic myeloid leukemia
November 15, 2000, Blood Journal
The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease
June 1998, Journal Blood
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).